Rapamycin vs. Metformin vs. GLP-1 Drugs: Which Longevity Therapy Has the Strongest Evidence in 2026?
Quick Summary The search for a scientifically proven "anti-aging drug" has never been more exciting. Three therapies dominate the longevity conversation in 2026: Rapamycin — the strongest experimental lifespan extender and mTOR inhibitor. Metformin — the widely used diabetes drug with decades of safety data and potential healthy-aging benefits. GLP-1 receptor agonists (Ozempic®, Wegovy®, Mounjaro®, Zepbound®) — originally developed for diabetes and obesity, now being investigated for their effects on aging, inflammation, cardiovascular disease, dementia, and cancer. Each works through different biological pathways and offers unique strengths. Bottom Line If the goal is maximizing lifespan in laboratory animals , rapamycin remains the clear leader. If the goal is improving metabolic health in humans , GLP-1 receptor agonists currently have the strongest clinical evidence. Metformin occupies the middle ground with an excellent safety profile and pro...